Kingswood Capital Partners Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$45 Price Target
Quantum BioPharma (NASDAQ: QNTM) has received analyst coverage initiation from Kingswood Capital Partners with a BUY rating and US$45 price target. The valuation is based on a discounted cash flow analysis assuming successful Phase 2 and 3 trials of Lucid-MS during 2026-2028, with anticipated commercial launch in 2029.
The coverage is led by Karen Sterling, PhD, CFA, Senior Equity Analyst at Kingswood Capital Partners. Notably, this is unpaid research with no consideration provided by Quantum BioPharma, which is developing innovative solutions for neurodegenerative, metabolic, and alcohol misuse disorders.
Quantum BioPharma (NASDAQ: QNTM) ha ricevuto una copertura dagli analisti di Kingswood Capital Partners con una valutazione BUY e un target price di US$45. La valutazione si basa su un modello di flussi di cassa scontati che presuppone il successo delle sperimentazioni di Fase 2 e 3 di Lucid‑MS nel periodo 2026‑2028, con un lancio commerciale previsto per il 2029.
La copertura è guidata da Karen Sterling, PhD, CFA, Senior Equity Analyst di Kingswood Capital Partners. È importante sottolineare che si tratta di ricerca non retribuita, senza alcun compenso fornito da Quantum BioPharma, azienda che sviluppa soluzioni innovative per i disturbi neurodegenerativi, metabolici e dell’abuso di alcol.
Quantum BioPharma (NASDAQ: QNTM) ha recibido cobertura de analistas por parte de Kingswood Capital Partners con una calificación BUY y un precio objetivo de US$45. La valoración se fundamenta en un análisis de flujo de caja descontado que asume el éxito de los ensayos de Fase 2 y 3 de Lucid‑MS entre 2026 y 2028, con un esperado lanzamiento comercial en 2029.
La cobertura está liderada por Karen Sterling, PhD, CFA, Senior Equity Analyst en Kingswood Capital Partners. Cabe destacar que se trata de investigación no remunerada, sin ninguna compensación por parte de Quantum BioPharma, que desarrolla soluciones innovadoras para trastornos neurodegenerativos, metabólicos y por abuso de alcohol.
Quantum BioPharma (NASDAQ: QNTM)가 Kingswood Capital Partners의 애널리스트 커버리지를 시작받아 BUY 의견과 목표주가 미화 45달러(US$45)를 제시받았습니다. 이 밸류에이션은 할인된 현금흐름(DCF) 분석을 기반으로 하며, 2026–2028년 사이 Lucid‑MS의 2상 및 3상 시험이 성공적일 것이라는 가정과 2029년 상업적 출시를 전제로 합니다.
커버리지는 Kingswood Capital Partners의 수석 주식 애널리스트인 Karen Sterling, PhD, CFA가 주도하고 있습니다. 주목할 점은 본 리포트가 Quantum BioPharma로부터 어떠한 대가도 받지 않은 무보수 연구라는 점이며, 해당 회사는 신경퇴행성 질환, 대사질환 및 알코올 남용 장애에 대한 혁신적 솔루션을 개발하고 있습니다.
Quantum BioPharma (NASDAQ: QNTM) a fait l’objet d’une couverture par les analystes de Kingswood Capital Partners avec une recommandation BUY et un objectif de cours de 45 $ US. L’évaluation repose sur une analyse par flux de trésorerie actualisés (DCF) supposant le succès des essais de phase 2 et 3 de Lucid‑MS entre 2026 et 2028, avec un lancement commercial attendu en 2029.
La couverture est menée par Karen Sterling, PhD, CFA, Senior Equity Analyst chez Kingswood Capital Partners. Il est important de noter qu’il s’agit d’une recherche non rémunérée, sans contrepartie de la part de Quantum BioPharma, qui développe des solutions innovantes pour les troubles neurodégénératifs, métaboliques et liés à l’abus d’alcool.
Quantum BioPharma (NASDAQ: QNTM) hat von Kingswood Capital Partners Analystencoverage mit einer BUY‑Einstufung und einem Kursziel von US$45 erhalten. Die Bewertung basiert auf einer Discounted‑Cash‑Flow‑Analyse, die von erfolgreichen Phase‑2‑ und Phase‑3‑Studien zu Lucid‑MS in den Jahren 2026–2028 ausgeht und einen kommerziellen Start für 2029 erwartet.
Die Coverage wird geleitet von Karen Sterling, PhD, CFA, Senior Equity Analyst bei Kingswood Capital Partners. Erwähnenswert ist, dass es sich um unbezahlte Forschung handelt und Quantum BioPharma dafür keinerlei Vergütung geleistet hat; das Unternehmen entwickelt innovative Lösungen für neurodegenerative, metabolische Erkrankungen und Alkoholmissbrauchsstörungen.
- None.
- None.
This was unpaid research with no consideration given
TORONTO, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announces Kingswood Capital Partners has initiated coverage of Quantum BioPharma with a BUY rating and a discounted cash flow based US
A copy of this report can be found at: Kingswood Analyst Report
About Quantum BioPharma Ltd.
Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Celly Nutrition Corp. (“Celly Nutrition”), now Unbuzzd Wellness Inc., led by industry veterans. Quantum BioPharma retains ownership of
For more information visit www.quantumbiopharma.com.
About Kingswood Capital Partners U.S.
Kingswood U.S. is a leading wealth management platform with more than 400 financial advisors and over
Kingswood U.S. operates a full-service Equity Capital Markets (ECM) platform out of Miami and New York, delivering institutional distribution, research-driven insights, and corporate finance advisory. The platform connects growth companies with a deep network of institutional investors and family offices, supported by a seasoned team with experience across sectors and market cycles.
For more information visit www.kingswoodus.com
About ArcStone Securities & Investments Corp.
ArcStone Securities & Investments Corp. is a cross-border investment bank with offices in New York, Toronto, and Florida, focused on serving growth-stage companies with market capitalizations between
ArcStone’s capabilities span roadshows, institutional marketing, proprietary trading, and investment banking across equity capital markets (ECM) and mergers & acquisitions (M&A). Since its founding, ArcStone has expanded through strategic acquisitions including the equity buy-in and rebrand of Arcview Capital (FINRA broker-dealer) to become one of the few firms that can offer both U.S. and Canadian clients seamless cross-border execution.
For more information visit www.arcstoneglobalsecurities.com
Forward-Looking Information
This press release contains forward-looking statements under applicable securities laws, identified by terms like "may," "should," "anticipate," "expect," "potential," "believe," or "intend." These statements, based on assumptions and expected future events, involve risks and uncertainties that may cause actual results to differ materially from those expressed. For more details on risks, see Quantum BioPharma’s filings on SEDAR+ (www.sedarplus.ca) and EDGAR (www.sec.gov). Readers should not rely unduly on these statements, as there is no assurance that plans or expectations will occur. The Company assumes no obligation to update these statements except as required by law.
The reader is urged to refer to additional information relating to Quantum BioPharma, including its annual information form, which can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the United States Securities and Exchange Commission’s website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.
Contacts:
Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com
Telephone: (833) 571-1811
Investor Relations
Investor Relations: IR@QuantumBioPharma.com
General Inquiries: info@QuantumBioPharma.com
FAQ
What is the price target set by Kingswood Capital Partners for Quantum BioPharma (QNTM)?
When is Lucid-MS expected to complete clinical trials for Quantum BioPharma (QNTM)?
Who initiated the analyst coverage for Quantum BioPharma (QNTM)?
Is the Kingswood Capital Partners coverage of QNTM paid research?
